Madrigal Pharmaceuticals Files 8-K on Financials
Ticker: MDGL · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1157601
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Madrigal Pharma dropped its 8-K on 10/31, check the financials!
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on October 31, 2024, reporting results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in West Conshohocken, Pennsylvania.
Why It Matters
This filing provides crucial updates on Madrigal Pharmaceuticals' financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- October 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- West Conshohocken, Pennsylvania (location) — Address of principal executive offices
- SYNTA PHARMACEUTICALS CORP (company) — Former company name
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated October 31, 2024.
Where are Madrigal Pharmaceuticals' principal executive offices located?
The principal executive offices are located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428.
What is Madrigal Pharmaceuticals' state of incorporation?
Madrigal Pharmaceuticals, Inc. is incorporated in Delaware.
Has Madrigal Pharmaceuticals undergone any previous name changes?
Yes, the company was formerly known as SYNTA PHARMACEUTICALS CORP, with a date of name change on August 15, 2001.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-31 07:05:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MDGL The Nasdaq
Filing Documents
- d788088d8k.htm (8-K) — 26KB
- d788088dex991.htm (EX-99.1) — 64KB
- g788088g1030092808638.jpg (GRAPHIC) — 3KB
- 0001193125-24-248137.txt ( ) — 228KB
- mdgl-20241031.xsd (EX-101.SCH) — 3KB
- mdgl-20241031_lab.xml (EX-101.LAB) — 18KB
- mdgl-20241031_pre.xml (EX-101.PRE) — 11KB
- d788088d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Madrigal Pharmaceuticals, Inc., dated October 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi C. Dier Name: Mardi C. Dier Title: Senior Vice President and Chief Financial Officer Date: October 31, 2024